Tri-Tech Biopharmaceuticals

Tritech Biopharmaceuticals is a Taiwan-based biotechnology company specializing in the development of non-invasive drug delivery systems, particularly transdermal and topical formulations. The company utilizes its proprietary High Throughput Screening Platform (HTSP) to identify effective transdermal enhancers and design drug dosages that offer long-lasting efficacy with reduced side effects. Tritech's pipeline includes treatments for osteoporosis, erectile dysfunction, and pulmonary arterial hypertension, with its lead candidate TR399 (a topical vardenafil gel) having completed Phase I/IIa trials. Headquartered in Taipei, the company operates out of the Biomedical Development Center of Mackay Memorial Hospital to advance its clinical research and development efforts.